Our experienced clinicians will guide you with regular reviews and ongoing support to ensure your success
[3] Gastrointestinal effects of tirzepatideincluding nausea, vomiting, and delayed gastric emptyingcould theoretically affect the absorption of oral medications
Chronic conditions may require longer treatment or multiple cycles
In addition, SoC in FLOW did include MRA treatment, but not the newer, more effective, ns-MRA therapies (e.g., finerenone), which have now been included in the treatment guidelines for CKD by the American Diabetes Association (ADA), KDIGO, the European Renal Association (ERA) and the Danish Nephrology Society (DNS) [12, 13, 58, 59]